Drug Profile
Lidocaine - NanoCyte/Ferndale Laboratories
Alternative Names: Lidocaine - NanoCyteLatest Information Update: 20 Jan 2022
Price :
$50
*
At a glance
- Originator NanoCyte
- Developer Ferndale Laboratories; NanoCyte
- Class Acetanilides; Class Ib antiarrhythmics; Local anaesthetics; Non-opioid analgesics; Small molecules
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Pain
Most Recent Events
- 02 Sep 2015 No recent reports on development identified - Phase-II for Pain in USA (Transdermal)
- 10 Feb 2009 Phase-II clinical trials in Pain in USA (Transdermal)
- 12 Mar 2008 Preclinical trials in Pain in USA (Transdermal)